Retinoic acid enhances the levels of IL-10 in TLR-stimulated B cells from patients with relapsing–remitting multiple sclerosis

Anderson, 1997, Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma, Biochem. Soc. Trans., 25, 705, 10.1042/bst0250705 Arnason, 2011, Tumour necrosis factor neutralization in MS: a cautionary tale, Int. MS J., 17, 63 Ascherio, 2010, Vitamin D and multiple sclerosis, Lancet Neurol., 9, 599, 10.1016/S1474-4422(10)70086-7 Balmer, 2002, Gene expression regulation by retinoic acid, J. Lipid Res., 43, 1773, 10.1194/jlr.R100015-JLR200 Bar-Or, 2010, Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?, Ann. Neurol., 67, 452, 10.1002/ana.21939 Ben-Nun, 1981, The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur. J. Immunol., 11, 195, 10.1002/eji.1830110307 Bernasconi, 2002, Maintenance of serological memory by polyclonal activation of human memory B cells, Science, 298, 2199, 10.1126/science.1076071 Besler, 2002, Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis, Nutr. Neurosci., 5, 215, 10.1080/10284150290029205 Bode, 2011, CpG DNA as a vaccine adjuvant, Expert Rev. Vaccines, 10, 499, 10.1586/erv.10.174 Broux, 2013, Which immune cells matter? The immunopathogenesis of multiple sclerosis, Crit. Rev. Immunol., 33, 283, 10.1615/CritRevImmunol.2013007453 Chambon, 1996, A decade of molecular biology of retinoic acid receptors, FASEB J., 10, 940, 10.1096/fasebj.10.9.8801176 Chaplin, 2011, Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway, J. Immunol., 187, 4199, 10.4049/jimmunol.1100198 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704 Comabella, 2012, Immunopathogenesis of multiple sclerosis, Clin. Immunol., 142, 2, 10.1016/j.clim.2011.03.004 Compston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7 Disanto, 2012, The evidence for a role of B cells in multiple sclerosis, Neurology, 78, 823, 10.1212/WNL.0b013e318249f6f0 Duddy, 2007, Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis, J. Immunol., 178, 6092, 10.4049/jimmunol.178.10.6092 Eriksen, 2012, TLR9-signaling is required for turning retinoic acid into a potent stimulator of RP105 (CD180)-mediated proliferation and IgG synthesis in human memory B cells, Cell. Immunol., 279, 87, 10.1016/j.cellimm.2012.09.003 Ertesvag, 2007, Vitamin A potentiates CpG-mediated memory B-cell proliferation and differentiation: involvement of early activation of p38MAPK, Blood, 109, 3865, 10.1182/blood-2006-09-046748 Ertesvag, 2009, Regulation of B cell proliferation and differentiation by retinoic acid, Semin. Immunol., 21, 36, 10.1016/j.smim.2008.06.005 Fillatreau, 2002, B cells regulate autoimmunity by provision of IL-10, Nat. Immunol., 3, 944, 10.1038/ni833 Fragoso, 2014, The evidence for a beneficial role of vitamin a in multiple sclerosis, CNS Drugs, 28, 291, 10.1007/s40263-014-0148-4 Freedman, 2005, Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement, Arch. Neurol., 62, 865, 10.1001/archneur.62.6.865 Gambuzza, 2011, Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management, J. Neuroimmunol., 239, 1, 10.1016/j.jneuroim.2011.08.010 Genain, 1999, Identification of autoantibodies associated with myelin damage in multiple sclerosis, Nat. Med., 5, 170, 10.1038/5532 Hall, 2011, The role of retinoic acid in tolerance and immunity, Immunity, 35, 13, 10.1016/j.immuni.2011.07.002 Harrirchian, 2014, The effect of vitamin a supplementation on disease progression, cytokine levels and gene expression in multiple sclerotic patients: study protocol for a randomized controlled trial, Acta Med. Iran, 52, 94 Hauser, 2008, B-cell depletion with rituximab in relapsing–remitting multiple sclerosis, N. Engl. J. Med., 358, 676, 10.1056/NEJMoa0706383 He, 2013, Rituximab for relapsing–remitting multiple sclerosis, Cochrane Database Syst. Rev., 12, CD009130 Hirotani, 2010, Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis, J. Neuroimmunol., 221, 95, 10.1016/j.jneuroim.2010.02.012 Hofman, 1989, Tumor necrosis factor identified in multiple sclerosis brain, J. Exp. Med., 170, 607, 10.1084/jem.170.2.607 Indrevaer, 2013, Retinoic acid improves defective TLR9/RP105-induced immune responses in common variable immunodeficiency-derived B cells, J. Immunol., 191, 3624, 10.4049/jimmunol.1300213 Ireland, 2012, Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity, Autoimmunity, 45, 400, 10.3109/08916934.2012.665529 Jafarirad, 2012, The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis, J. Neurosci. Rural Pract., 3, 294, 10.4103/0976-3147.102609 Knippenberg, 2011, Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission, J. Neuroimmunol., 239, 80, 10.1016/j.jneuroim.2011.08.019 Krieg, 1995, CpG motifs in bacterial DNA trigger direct B-cell activation, Nature, 374, 546, 10.1038/374546a0 Kumar, 2009, Toll-like receptors and innate immunity, Biochem. Biophys. Res. Commun., 388, 621, 10.1016/j.bbrc.2009.08.062 Lampropoulou, 2008, TLR-activated B cells suppress T cell-mediated autoimmunity, J. Immunol., 180, 4763, 10.4049/jimmunol.180.7.4763 Lassmann, 2007, The immunopathology of multiple sclerosis: an overview, Brain Pathol., 17, 210, 10.1111/j.1750-3639.2007.00064.x Link, 2006, Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness, J. Neuroimmunol., 180, 17, 10.1016/j.jneuroim.2006.07.006 Loken-Amsrud, 2013, Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis, Mult. Scler., 19, 451, 10.1177/1352458512457843 Maimone, 1991, Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis, J. Neuroimmunol., 32, 67, 10.1016/0165-5728(91)90073-G Marta, 2008, Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis, Eur. J. Immunol., 38, 565, 10.1002/eji.200737187 McGeachy, 2007, TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology, Nat. Immunol., 8, 1390, 10.1038/ni1539 Miyake, 1994, Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells, J. Exp. Med., 180, 1217, 10.1084/jem.180.4.1217 Miyake, 1995, RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family, J. Immunol., 154, 3333, 10.4049/jimmunol.154.7.3333 Mora, 2008, Vitamin effects on the immune system: vitamins A and D take centre stage, Nat. Rev. Immunol., 8, 685, 10.1038/nri2378 Naderi, 1999, Retinoic acid prevents phosphorylation of pRB in normal human B lymphocytes: regulation of cyclin E, cyclin A, and p21(Cip1), Blood, 94, 1348, 10.1182/blood.V94.4.1348 Napoli, 1996, Retinoic acid biosynthesis and metabolism, FASEB J., 10, 993, 10.1096/fasebj.10.9.8801182 Noseworthy, 2000, Multiple sclerosis, N. Engl. J. Med., 343, 938, 10.1056/NEJM200009283431307 Ochsenbein, 2000, Natural antibodies and complement link innate and acquired immunity, Immunol. Today, 21, 624, 10.1016/S0167-5699(00)01754-0 O'Connor, 2002, Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population, J. Exp. Med., 195, 737, 10.1084/jem.20011626 Piccio, 2010, Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis, Arch. Neurol., 67, 707, 10.1001/archneurol.2010.99 Polman, 2011, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann. Neurol., 69, 292, 10.1002/ana.22366 Prinz, 2006, Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis, J. Clin. Invest., 116, 456, 10.1172/JCI26078 Raine, 1999, Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation, Ann. Neurol., 46, 144, 10.1002/1531-8249(199908)46:2<144::AID-ANA3>3.0.CO;2-K Ramagopalan, 2010, Multiple sclerosis: risk factors, prodromes, and potential causal pathways, Lancet Neurol., 9, 727, 10.1016/S1474-4422(10)70094-6 Ramgolam, 2011, B cells as a therapeutic target for IFN-beta in relapsing–remitting multiple sclerosis, J. Immunol., 186, 4518, 10.4049/jimmunol.1000271 Reff, 1994, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83, 435, 10.1182/blood.V83.2.435.435 Ross, 2011, Vitamin A and retinoic acid in the regulation of B-cell development and antibody production, Vitam. Horm., 86, 103, 10.1016/B978-0-12-386960-9.00005-8 Sharief, 1991, Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis, N. Engl. J. Med., 325, 467, 10.1056/NEJM199108153250704 Solomon, 2011, Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors, Mult. Scler., 17, 1472, 10.1177/1352458511412996 Stepien, 2013, Effects of interferon beta-1a and interferon beta-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing–remitting multiple sclerosis: a 3-year longitudinal study, Neuroimmunomodulation, 20, 213, 10.1159/000348701 Storch, 1998, Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination, Ann. Neurol., 43, 465, 10.1002/ana.410430409 Tangye, 2004, Divide and conquer: the importance of cell division in regulating B-cell responses, Immunology, 112, 509, 10.1111/j.1365-2567.2004.01950.x The IFNB Multiple Sclerosis Study Group, 1993, Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, 655, 10.1212/WNL.43.4.655 Traggiai, 2003, Antigen dependent and independent mechanisms that sustain serum antibody levels, Vaccine, 21, S35, 10.1016/S0264-410X(03)00198-1 Trapp, 2008, Multiple sclerosis: an immune or neurodegenerative disorder?, Annu. Rev. Neurosci., 31, 247, 10.1146/annurev.neuro.30.051606.094313 Vandenbark, 1985, A myelin basic protein-specific T lymphocyte line that mediates experimental autoimmune encephalomyelitis, J. Immunol., 135, 223, 10.4049/jimmunol.135.1.223 Yamazaki, 2010, Potentiation of TLR9 responses for human naive B-cell growth through RP105 signaling, Clin. Immunol., 135, 125, 10.1016/j.clim.2009.12.013 Ziemssen, 2007, Glatiramer acetate: mechanisms of action in multiple sclerosis, Int. Rev. Neurobiol., 79, 537, 10.1016/S0074-7742(07)79024-4